Keyphrases
Glucagon-like peptide-1 Receptor (GLP-1R)
100%
Brief Assessment of Cognition in Schizophrenia
100%
Obese Patients
100%
Cognitive Effects
100%
Patients with Schizophrenia
100%
Agonism
100%
Antipsychotics
100%
Glucagon-like
66%
Performance Scale
66%
Receptor Agonist
66%
Time Effect
66%
A1 Receptor
66%
Short Form 36 (SF-36)
66%
Composite Score
66%
Negative Syndrome
66%
Social Performance
66%
Individual Performance
66%
Metabolic Effects
66%
Short Form Health Survey
33%
Spectrum Disorder
33%
Diabetes Management
33%
Randomized Placebo-controlled Trial
33%
Schizophrenia
33%
Clinical Trials
33%
Repeated Measures Analysis of Variance
33%
Exenatide
33%
Obesity Treatment
33%
Placebo
33%
Group Interaction
33%
Investigator-initiated
33%
Psychosocial Impairment
33%
Cognitive Impairment
33%
Schizophrenia Spectrum Disorders
33%
Exenatide Once Weekly
33%
Patients with Obesity
33%
Pharmacology, Toxicology and Pharmaceutical Science
Antipsychotic
100%
Glucagon-Like Peptide 1 Receptor
100%
Exendin 4
100%
Positive Syndrome
66%
Placebo
66%
Glucagon Like Peptide 1 Receptor Agonist
66%
Negative Syndrome
66%
Health Survey
33%
Diseases
33%
Clinical Trial
33%
Neuroscience
Glucagon-Like Peptide 1 Receptor
100%
Antipsychotic
100%
Exenatide
100%
Negative Syndrome
66%
Positive Syndrome
66%
Placebo
66%
Glucagon-Like Peptide-1 Agonist
66%
Spectrum Disorder
33%